

Biocon Biologics (Thailand) Co., Ltd.**BALANCE SHEET AS AT MARCH 31, 2024**

(All amounts in THB Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>March 31, 2024</u>
ASSETS		
Non-current assets		
Deferred tax asset (net)		78
Total non-current assets		78
Current assets		
Financial assets		
(i) Trade receivables	1	25,633
Total current assets		25,633
TOTAL		25,711
EQUITY AND LIABILITIES		
Equity		
Equity share capital	2	25,000
Other equity	3	(266)
Total equity		24,734
Current liabilities		
Financial liabilities		
(i) Trade payables	4	862
Income-tax liability (net)		11
Provisions	5	58
Other current liabilities	6	46
Total current liabilities		977
TOTAL		25,711

Biocon Biologics (Thailand) Co., Ltd.**STATEMENT OF PROFIT AND LOSS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in THB Thousands, except share data and unless otherwise stated)

	<u>Notes</u>	<u>Period ended</u> <u>March 31, 2024</u>
Income		
Other operating income	7	633
Total revenue (I)		633
Expenses		
Employee benefits expense	8	603
Other expenses	9	363
Total expenses (II)		966
Profit before tax		(333)
Tax expense		
Current tax		11
Deferred Tax		(78)
Total tax expense		(67)
Profit for the period		(266)

Biocon Biologics (Thailand) Co., Ltd.**STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED MARCH 31, 2024**

(All amounts in THB Thousands, except share data and unless otherwise stated)

	Period ended March 31, 2024
I Cash flows from operating activities	
Profit after tax	(266)
<u>Adjustments to reconcile profit before tax to net cash flows:</u>	
Tax expense	(67)
Operating profit before working capital changes	<u>(333)</u>
Movements in working capital	
Decrease/(Increase) in trade receivables	(25,633)
Increase in trade payable, other liabilities and provisions	966
Cash generated used in operations	<u>(25,000)</u>
Direct taxes paid	-
Net cash flow (used in) operating activities	<u><u>(25,000)</u></u>
II Cash flows from investing activities	
Net cash flow (used in) investing activities	<u><u>-</u></u>
III Cash flows from financing activities	
Proceeds from issue of equity shares	25,000
Net cash flow generated from financing activities	<u><u>25,000</u></u>
IV Net increase/(decrease) in cash and cash equivalents (I + II + III)	-
V Effect of exchange differences on cash and cash equivalents held in foreign currency	-
VI Cash and cash equivalents at the beginning of the year	-
VIII Cash and cash equivalents at the end of the year (IV + V + VI)	<u><u>-</u></u>
Reconciliation of cash and cash equivalents as per statement of cash flow	
Cash and cash equivalents	
Balances with banks - on current accounts	-
Cash on hand	-
Total cash and cash equivalents	<u><u>-</u></u>

Biocon Biologics (Thailand) Co., Ltd.**Notes to financial statements for the period ended March 31, 2024**

(All amounts in THB Thousands, except share data and unless otherwise stated)

March 31, 2024**1. Trade receivables****Other Receivables**Outstanding for a period less than six months from the date they are due for payment
Unsecured, considered good

25,633

25,633**2. Share capital**

Equity share 10,00,000 common stock of THB 25 each paid up

25,000

25,000**3. Other equity****Surplus/(deficit) in the statement of profit and loss**

Balance as per the last financial statements

-

Profit / (Loss) for the period

(266)**Net surplus/(deficit) in the statement of profit and loss**(266)**Total other equity**(266)**4. Trade payables**862**5. Provisions****Current**

Compensated absences

58

58**6. Other liabilities****(a) Current liabilities**

Statutory liabilities

46

46

Biocon Biologics (Thailand) Co., Ltd.

Notes to financial statements for the period ended March 31, 2024

(All amounts in THB Thousands, except share data and unless otherwise stated)

	Period ended
	March 31, 2024
	<hr/>
7. Other operating income	
Support service cross charge to Group Companies	633
	<hr/> 633
8. Employee benefits expense	
Salaries, wages and bonus	603
	<hr/> 603
9. Other expenses	
Legal and professional fees	363
	<hr/> 363